Co-Diagnostics, Inc. (MUN:C970)
Germany · Delayed Price · Currency is EUR 9.96
-0.54 (-5.14%)
At close: Nov 26, 2025
Co-Diagnostics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 0.51 | 0.77 | 0.99 | 34.22 | 97.89 | 74.55 |
Other Revenue | - | 3.15 | 5.82 | - | - | - |
| 0.51 | 3.92 | 6.81 | 34.22 | 97.89 | 74.55 | |
Revenue Growth (YoY) | -93.06% | -42.53% | -80.09% | -65.04% | 31.30% | 34579.89% |
Cost of Revenue | 0.34 | 1 | 4.18 | 5.48 | 11.57 | 16.59 |
Gross Profit | 0.17 | 2.92 | 2.63 | 28.74 | 86.31 | 57.96 |
Selling, General & Admin | 15.66 | 20.64 | 21.14 | 21.61 | 24.95 | 12.94 |
Research & Development | 18.85 | 20.98 | 22.96 | 17.44 | 14.96 | 3.19 |
Operating Expenses | 35.7 | 43 | 45.33 | 40.33 | 40.25 | 16.27 |
Operating Income | -35.53 | -40.08 | -42.71 | -11.59 | 46.06 | 41.69 |
Interest & Investment Income | 0.16 | 1.09 | 1.16 | 0.7 | 0.05 | 0.1 |
Earnings From Equity Investments | -0.12 | -0.19 | 0.1 | -0.33 | -0.43 | 0.78 |
EBT Excluding Unusual Items | -35.49 | -39.18 | -41.44 | -11.22 | 45.68 | 42.57 |
Impairment of Goodwill | - | - | - | -15.39 | - | - |
Gain (Loss) on Sale of Investments | 0.96 | 0.87 | 2.24 | - | - | - |
Gain (Loss) on Sale of Assets | -0 | 0.01 | -0 | -0.14 | -0.04 | -0 |
Other Unusual Items | 1.21 | 0.71 | 1.09 | 7.9 | - | - |
Pretax Income | -33.33 | -37.58 | -38.11 | -18.85 | 45.64 | 42.57 |
Income Tax Expense | -1.15 | 0.06 | -2.78 | -4.61 | 8.98 | 0.09 |
Net Income | -32.18 | -37.64 | -35.33 | -14.24 | 36.66 | 42.48 |
Net Income to Common | -32.18 | -37.64 | -35.33 | -14.24 | 36.66 | 42.48 |
Net Income Growth | - | - | - | - | -13.70% | - |
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 |
Shares Change (YoY) | 11.72% | 3.37% | -6.77% | 5.27% | 6.80% | 67.10% |
EPS (Basic) | -28.82 | -37.22 | -36.12 | -13.57 | 38.09 | 47.69 |
EPS (Diluted) | -29.01 | -37.22 | -36.12 | -13.57 | 36.90 | 45.60 |
EPS Growth | - | - | - | - | -19.08% | - |
Free Cash Flow | -31.81 | -29.9 | -23.45 | 5.14 | 40.41 | 27.39 |
Free Cash Flow Per Share | -28.49 | -29.57 | -23.97 | 4.90 | 40.54 | 29.35 |
Gross Margin | 34.03% | 74.48% | 38.56% | 83.98% | 88.17% | 77.75% |
Operating Margin | -6995.70% | -1023.75% | -626.92% | -33.88% | 47.06% | 55.93% |
Profit Margin | -6336.27% | -961.37% | -518.68% | -41.61% | 37.45% | 56.98% |
Free Cash Flow Margin | -6263.08% | -763.79% | -344.20% | 15.02% | 41.28% | 36.74% |
EBITDA | -34.33 | -38.7 | -41.48 | -10.31 | 46.4 | 41.83 |
EBITDA Margin | - | - | - | -30.13% | 47.40% | 56.11% |
D&A For EBITDA | 1.2 | 1.38 | 1.23 | 1.28 | 0.34 | 0.14 |
EBIT | -35.53 | -40.08 | -42.71 | -11.59 | 46.06 | 41.69 |
EBIT Margin | - | - | - | -33.88% | 47.06% | 55.93% |
Effective Tax Rate | - | - | - | - | 19.67% | 0.21% |
Revenue as Reported | 0.51 | 3.92 | 6.81 | 34.22 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.